Quantum BioPharma Ltd. (NASDAQ: QNTM) is advancing its lead drug candidate, Lucid-MS, toward a randomized, double-blind, placebo-controlled Phase 2 clinical trial in multiple sclerosis (MS) after the U.S. Food and Drug Administration (FDA) cleared its Investigational New Drug (IND) application. The announcement signals a critical milestone for the company and offers a potential new avenue for treating a disease that affects millions worldwide.
Lucid-MS is a patented, first-in-class, non-covalent inhibitor of peptidyl arginine deiminase 2 (PAD2). Unlike existing MS therapies that primarily suppress the immune system, Lucid-MS is designed to target demyelination directly, aiming to prevent and reverse the degradation of myelin—the protective sheath around nerve fibers that is damaged in MS. This mechanism could address a significant unmet need for patients who do not respond adequately to current immunosuppressive treatments.
The FDA's clearance of the IND application allows Quantum BioPharma to proceed with planning the Phase 2 trial, which will evaluate the safety and efficacy of Lucid-MS in MS patients. The trial's randomized, double-blind, placebo-controlled design is the gold standard for clinical research, providing robust data to support potential future regulatory submissions.
In addition to the clinical advancement, Quantum BioPharma is collaborating with Massachusetts General Hospital and Harvard Medical School on research involving the [¹⁸F]3F4AP PET imaging tracer. This tracer is being evaluated as a method to visualize and measure demyelination, which could enhance the ability to diagnose and monitor MS progression and treatment response. Such imaging tools are crucial for developing therapies that target remyelination.
The news places Quantum BioPharma alongside other companies making strides in areas of unmet medical need. Novartis AG (NYSE: NVS) recently received FDA approval for Pluvicto® in combination with an androgen receptor pathway inhibitor for certain patients with metastatic hormone-sensitive prostate cancer. Merck & Co. Inc. (NYSE: MRK) had its supplemental Biologics License Application for ENFLONSIA™ accepted by the FDA to expand its indication for certain children at increased risk for severe respiratory syncytial virus disease. TG Therapeutics Inc. (NASDAQ: TGTX) initiated a Phase 2 trial of BRIUMVI® in adults with treatment-resistant schizophrenia. Bristol-Myers Squibb Company (NYSE: BMY) reported positive Phase 2 results from the registrational QUINTESSENTIAL trial evaluating arlocabtagene autoleucel in heavily pretreated relapsed and refractory multiple myeloma.
Quantum BioPharma is a biopharmaceutical company dedicated to building a portfolio of innovative assets for neurodegenerative and metabolic disorders, as well as alcohol misuse disorders. Through its wholly owned subsidiary, Lucid Psycheceuticals Inc., the company focuses on Lucid-MS. Quantum also invented UNBUZZD™ and spun out its OTC version to Unbuzzd Wellness Inc., retaining a 19.84% ownership stake (as of March 31, 2026) and royalty rights. The agreement includes a 7% royalty on sales until payments reach $250 million, after which the royalty drops to 3% in perpetuity. Quantum retains 100% of the rights to develop similar products for pharmaceutical and medical uses.
For investors, the FDA clearance de-risks the next stage of development for Lucid-MS and could attract partnership or financing interest. The MS market is substantial, and a therapy with a novel mechanism could capture significant share if proven effective. The collaboration with Harvard and MGH further validates the scientific approach.
